Which pharmacologic treatments are appropriate for a patient with an eating disorder, and how can a booster dose be administered for the selected medication?

Pharmacologic Treatment for Eating Disorders

The specific medications for treating eating disorders depend entirely on the diagnosis: for bulimia nervosa, use fluoxetine 60 mg daily (either initially or if minimal response to psychotherapy by 6 weeks); for binge-eating disorder, use either an antidepressant or lisdexamfetamine if the patient prefers medication or hasn't responded to psychotherapy alone; for anorexia nervosa, psychotherapy is primary and no specific pharmacotherapy is recommended. 1

Treatment Algorithm by Eating Disorder Type

Bulimia Nervosa

• Start with eating disorder-focused cognitive-behavioral therapy
• Add fluoxetine 60 mg daily either:
  • Initially (combined with psychotherapy), OR
  • If minimal or no response to psychotherapy alone by 6 weeks 1
• This is a formal APA recommendation (1C level) 1
• Fluoxetine is FDA-approved for bulimia nervosa and is relatively safe and well-tolerated 2

Binge-Eating Disorder

• First-line: Eating disorder-focused cognitive-behavioral therapy or interpersonal therapy 1
• Medication options (APA suggestion 2C level) for adults who prefer medication or have not responded to psychotherapy alone:
  • Lisdexamfetamine (only FDA-approved medication for BED) 3, 4, 5
  • Antidepressant medication (alternative option) 1
• Lisdexamfetamine is generally well-tolerated and effective for reducing binge eating episodes 3, 4

Anorexia Nervosa

• No specific pharmacotherapy is recommended 1
• Primary treatment is eating disorder-focused psychotherapy for adults (1B recommendation) 1
• Family-based treatment for adolescents and emerging adults with involved caregivers (1B recommendation) 1
• Medications have limited evidence for benefit in anorexia nervosa 5

Regarding "Booster" Dosing

The guidelines do not specify "booster" dosing strategies for eating disorder medications. The evidence provided discusses standard dosing regimens:

• Fluoxetine for bulimia nervosa: 60 mg daily (this is already a higher dose than typical antidepressant dosing) 1
• Lisdexamfetamine for BED: Standard FDA-approved dosing applies 3, 4

If you're asking about augmentation strategies or dose adjustments:

• For inadequate response to fluoxetine in bulimia nervosa: The guideline recommends adding it if psychotherapy alone fails by 6 weeks, but doesn't specify dose escalation beyond 60 mg daily
• For BED with inadequate response: Consider switching between medication classes (antidepressant vs. lisdexamfetamine) rather than "boosting" 1

Critical Caveats

Important monitoring requirements:

• ECG monitoring is required for patients with restrictive eating disorders, severe purging behavior, or those taking QTc-prolonging medications 1
• Comprehensive metabolic panel including electrolytes, liver enzymes, and renal function 1
• Lisdexamfetamine carries stimulant-related risks and requires appropriate screening and monitoring 2, 4

Psychotherapy remains the cornerstone:

• Medication is never a standalone treatment for eating disorders 1
• All patients require a multidisciplinary treatment plan incorporating medical, psychiatric, psychological, and nutritional expertise 1
• For anorexia nervosa specifically, psychotherapy has stronger evidence (1B) than any pharmacologic intervention 1

Comorbidity considerations:

• When depression or anxiety co-occurs with BED, antidepressants may address both conditions simultaneously 3
• This can guide medication selection between antidepressants and lisdexamfetamine for BED 3